Table 4.

Stratified analysis of change in insulin, IGF-I, and IGFBP-3 [mean (SE)]

ΔInsulinPΔIGF-IPΔIGFBP-3P
Age <56 y
    Exercisers, n = 190.51 (3.41)0.50−0.64 (7.65)0.20−0.05 (0.08)0.24
    Controls, n = 154.06 (3.86)14.99 (8.66)0.11 (0.10)
Age ≥56 y
    Exercisers, n = 17−4.51 (2.81)0.057−14.84 (9.33)0.064−0.36 (0.13)0.0047
    Controls, n = 173.38 (2.81)10.65 (9.33)0.20 (0.13)
0.53*0.60*0.22*
BMI <30 kg/m2
    Exercisers, n = 161.89 (4.60)0.57−12.81 (9.62)0.017−0.14 (0.12)0.0070
    Controls, n = 205.55 (4.06)19.70 (8.59)0.34 (0.11)
BMI ≥30 kg/m2
    Exercisers, n = 20−4.49 (2.06)0.18−2.49 (7.39)0.83−0.23 (0.10)0.78
    Controls, n = 120.23 (2.67)0.18 (9.55)−0.18 (0.13)
0.40*0.098*0.062*
No change or increased % body fat
    Exercisers, n = 12−3.36 (3.29)0.17−7.37 (7.10)0.0045−0.27 (0.09)0.0049
    Controls, n = 204.70 (4.59)30.11 (10.04)0.21 (0.13)
Decreased % body fat
    Exercisers, n = 24−2.16 (3.30)0.59−5.37 (10.38)0.63−0.02 (015)0.53
    Controls, n = 122.19 (2.62)1.07 (8.03)0.10 (0.12)
0.25*0.11*0.16*
Breast cancer stage 0 or I
    Exercisers, n = 24−3.17 (2.31)0.275.71 (6.88)0.30−0.19 (0.11)0.012
    Controls, n = 121.25 (3.21)18.34 (9.75)0.31 (0.15)
Breast cancer stage II or III
    Exercisers, n = 122.65 (4.72)0.85−30.54 (10.56)0.0080−0.20 (0.13)0.16
    Controls, n = 203.83 (3.70)7.53 (8.18)0.04 (0.10)
0.34*0.15*0.37*
Hormone therapy
None
    Exercisers, n = 15−2.72 (2.54)0.16−7.78 (9.99)0.024−0.21 (0.14)0.0063
    Controls, n = 93.34 (3.28)34.20 (13.18)0.52 (0.18)
Tamoxifen
    Exercisers, n = 11−5.85 (3.60)0.296.41 (9.53)0.80−0.25 (0.11)0.26
    Controls, n = 80.07 (4.02)2.58 (11.18)−0.05 (0.13)
Aromatase inhibitors
    Exercisers, n = 104.83 (5.62)0.99−22.90 (10.42)0.044−0.14 (0.15)0.34
    Controls, n = 154.79 (4.72)5.88 (8.51)0.05 (0.12)
0.48*0.64*0.25*
  • * P for interaction.